Exact Sciences Corporation (EXAS)

The most significant stock event was the announcement of Abbott Laboratories acquiring EXACT Sciences for approximately $21 billion, causing a substantial surge in EXAS stock. The stock rose by 17% on November 20, 2025, closing at its highest level in four years. Prior to the acquisition announcement, the company experienced a sell-off and a roughly 25% drop in share price due to a slight guidance cut and a narrow revenue miss in Q3 2024.

Demand for EXACT Sciences' products and services can experience some seasonality, with a severe flu season in Q1 potentially impacting patient access to testing. The number of individuals eligible for Cologuard rescreening is projected to increase annually, indicating a growing, recurring demand component. The full rollout of new products like Cologuard Plus is also dependent on securing broader commercial payer contracts, suggesting that market penetration and demand ramp-up for new offerings may not be uniform throughout the year.

EXACT Sciences Corp. is a molecular diagnostics company specializing in early cancer detection and prevention, operating in the healthcare sector. Its headquarters are in Madison, Wisconsin. Key products include Cologuard, a non-invasive stool-based DNA test for colorectal cancer screening; Oncotype DX, a suite of genomic tests for personalized treatment decisions in breast, colon, and prostate cancers; OncoExTra, a liquid-based comprehensive genomic profiling test; Cancerguard, a multi-cancer early detection blood test; and Oncodetect, a test for identifying molecular residual disease. The company is also developing pipeline products for various cancers.

EXACT Sciences Corp. has a significant presence in the United States, with facilities in Madison, Wisconsin, and Boston, Massachusetts. Internationally, the company has offices and labs in Switzerland, the United Kingdom, Italy, Germany, France, Japan, and Poland. Its subsidiaries, such as Genomic Health Inc. and PreventionGenetics LLC, also contribute to its global reach.

EXACT Sciences has maintained its reputation as a leader in cancer screening and precision oncology diagnostics. The company's flagship product, Cologuard, is recognized for revolutionizing colorectal cancer screening. The acquisition by Abbott Laboratories in November 2025 highlights the perceived value and strength of EXACT Sciences' product portfolio. However, there have been some concerns raised by employees regarding potential layoffs following the acquisition.

EXACT Sciences Corp. has a high level of institutional ownership, ranging from approximately 89% to 97.23%. Major institutional owners include Fmr Llc, Vanguard Group Inc., Capital World Investors, BlackRock, Inc., and State Street Corp. Individual investors hold approximately 10% to 19.75% of the stock, while insiders own about 0.8% to 1.04% of the company's shares.